Houston, TX – October 20th, 2025 – OmniScience has been recognized as a Vendor to Watch in the inaugural IDC MarketScape: Worldwide Life Sciences R&D AI (Including GenAI) in Clinical Trials 2025 Vendor Assessment.

This first-of-its-kind IDC MarketScape evaluates leading technology providers advancing the use of AI, including generative AI, in clinical trial solutions and services. OmniScience has been included and highlighted for its innovative approach to unifying clinical data and bringing explainable, agentic AI to clinical trials through its platform, Vivo.

IDC MarketScape reports provide an independent, data-driven assessment of technology vendors. Reports combine quantitative analysis, including market share, capabilities, growth, innovation, with qualitative insights, including strategy, customer perception, future readiness, to create a visual, comparative framework that helps buyers quickly understand which vendors are leaders, major players, contenders, or participants — and why.

“We’re honored to be named by IDC as a vendor to watch,” said Angela Holmes, CEO and Co-Founder of OmniScience. “This recognition reinforces the growing need for real-time, intelligent systems that help life sciences organizations move faster, reduce trial complexity, and deliver better outcomes.”